Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

150%

6 of 4 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

1(33.3%)

Phase 3

1(33.3%)

Phase 4

1(33.3%)

3Total

Phase 2(1)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02349386Phase 2Terminated

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

Role: collaborator

NCT02656329Phase 3Terminated

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device

Role: collaborator

NCT01952678Completed

Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)

Role: collaborator

NCT02127307Completed

Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

Role: collaborator

NCT02090855Completed

Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem

Role: collaborator

NCT01936649Phase 4Completed

Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.

Role: collaborator

All 6 trials loaded